Prostate News Archive
01-Jul-2011
Medicare Will Pay for Pricey Prostate Cancer Drug
THURSDAY, June 30 (HealthDay News) -- The cost of Provenge, an expensive and newly approved therapeutic prostate cancer vaccine, will be covered by Medicare for men with metastatic prostate cancer, the agency announced late Thursday. Medicare confirms payment for prostate cancer drug
Medicare officials confirmed Thursday that the program will cover the $93,000 price tag for prostate cancer drug Provenge, an innovative therapy that typically gives men suffering from an incurable stage of the disease an extra four months to live. Life after prostate surgery worse than men expect
NEW YORK (Reuters Health) - Nearly half of men who undergo surgery to treat prostate cancer find themselves with greater incontinence problems and less sexual function than they had anticipated, according to a new poll.
Back to Prostate News Archive
